Date: 2014-12-02
Type of information: R&D agreement
Compound: screening services, HTS and ADME profiling services
Company: Bioversys (Switzerland) Enamine (Ukraine )
Therapeutic area: Infectious diseases
Type agreement:
Action mechanism:
Disease:
Details: * On December 2, 2014, Enamine and BioVersys announced the extension of their drug discovery collaboration for the 4th consecutive year. Since the start of the collaboration Enamine has provided expertise in screening of compounds and chemistry know-how for hit finding activities and optimization. BioVersys has brought its unique approach and knowledge of antimicrobial resistance into the partnership. The new agreement covers further involvement of Enamine’s HTS platform and ADME profiling capabilities. Enamine has expanded its team of medicinal chemists to support the collaboration. The IP generated by the collaboration is owned by BioVersys. BioVersys focuses on research and development of small molecules which switch off drug resistance against existing antibiotics. With the company’s award-winning TRIC technology it will be possible to restore the efficacy of established antibiotics. BioVersys\' compounds will be used in combination with existing antibiotics, thereby renewing efficacy as well as intellectual property for the established drug. The current research focus is on nosocomial infections (hospital infections) and tuberculosis. In collaboration with GSK and a consortium of the University of Lille BioVersys aims to develop an effective treatment against tuberculosis. Established in Kiev in 1991, Enamine is a medicinal chemistry driven company, provider of innovative screening libraries, building blocks, comprehensive chemistry support in hit development, and integrated drug discovery services. Enamine’s design and synthesis capabilities allow the addition of more than 250,000 new organic compounds to its catalogue each year. Enamine offers collaborative expertise to exclusively design and supply libraries of new, potentially bioactive organic compounds. Enamine serves the pharmaceutical, agrochemical, cosmetic, nutritional and petrochemical industries.
Financial terms: Financial details were not disclosed.
Latest news:
